Abstract:
The second-most prevalent neurological disease in the world, Parkinson's disease (PD) affects
roughly 4 million people. The death and loss of dopaminergic neurons in the substantia nigra
compacta (SNpc) is the primary pathogenic characteristic of PD. Motor abnormalities include limb
stiffness, tremor, and bradykinesia are the major features of PD. Although levodopa (L-DOPA) is
the gold standard medication, but it has clear negative effects when taken over an extended period.
Therefore, it is vital that novel medicines and ideal therapeutic agents be discovered. Parkinson's
disease remains an unsolved clinical problem, as currently authorized PD therapies offer relatively
modest therapeutic benefits. New therapeutic approaches that not only alleviate symptoms in the
short term but also stop the disease from getting worse are desperately needed. For this purpose,
mice model is utilized for PD induction by MPTP neurotoxin for functional characterization of
proteomic factor GFAP as a risk factor in an effort to enhance the efficacy of the treatment of PD.
In future, by targeting pathway of GFAP level in substantia nigra with some targeted drug will
eventually lead to innovative therapeutic approach for PD patients.
